ProcaterolProcaterol
MedChemExpress (MCE)
HY-114732
72332-33-3
Please store the product under the recommended conditions in the Certificate of Analysis.
Room temperature in continental US
may vary elsewhere.
Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes.
Procaterol (10-1000 ng/mL, 12, 24, 48 h, BEAS-2B) directly inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism[3]. Procaterol (10-1000 ng/mL, 12, 24, 48 h, BEAS-2B) Dose-dependent inhibition of RANTES release in response to IL-1b and TNF-a in BEAS-2B cell monolayers, and enhancement of GM-CSF mRNA expression in response to IL-1b[3]. Procaterol (0.1 μM, 72 h, Human tracheal surface epithelial cells) reduce rhinovirus titers and RNA, cytokine concentrations, susceptibility to rhinovirus infection, and the expression of intercellular adhesion molecule-1 (ICAM-1), the receptor for type 14 rhinovirus, and the number of acidic endosomes in the cells from which rhinovirus RNA enters into the cytoplasm[4]. Procaterol (10 nM, one time, Lung epithelial cells) increased ciliary bend amplitude (CBA) and ciliary beating frequency (CBF) in a dose dependent manner via cAMP[5].
Procaterol (0.03-1 mg/kg, inhalation 3 times a day, 14 days) has no significant changes in weight or body weight gain in rat gastrocnemius muscle[1]. Procaterol (1 mg/kg, inhalation 3 times a day, 14 days) significantly increases weight of the levator ani muscle with anabolic effects[1]. Procaterol (1 mg/kg, inhalation 3 times a day, 14 days) increases ventral prostate weight is associated with drug stimulation of b2 adrenergic receptors in tissues[1]. Procaterol (0.03-1 mg/kg, inhalation 3 times a day, 14 days) different dose between bronchodilator and anabolic effects >30-fold, [1]. Procaterol (0.1, 1, 10 mg/kg, orally, before ovalbumin (HY-W250978) (OVA) inhalation) inhaler does not enhance airway hyperresponsiveness, airway wall inflammation, or airway wall thickening, and decreases eosinophil number[2].
β2 adrenoceptor
| | | |
| | | | | |
[1]. Ikezono K, et al. Bronchodilating effect and anabolic effect of inhaled procaterol. Int J Sports Med. 2008 Nov
29(11):888-94. [Content Brief]
[2]. Tashimo H, et al. Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. Allergol Int. 2007 Sep
56(3):241-7. [Content Brief]
[3]. Koyama S, et al. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur Respir J. 1999 Oct
14(4):767-75. [Content Brief]
[4]. Yamaya M, et al. Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Eur J Pharmacol. 2011 Jan 10
650(1):431-44. [Content Brief]
[5]. Komatani-Tamiya N, et al. Procaterol-stimulated increases in ciliary bend amplitude and ciliary beat frequency in mouse bronchioles. Cell Physiol Biochem. 2012
29(3-4):511-22. [Content Brief]